Advances in Cancer Immunotherapy™ - Buffalo, NY

When:  Mar 24, 2018 from 8:00 AM to 2:00 PM (ET)


Organizers: sitc_log_color.png

Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center
Marc Ernstoff, MD – Roswell Park Comprehensive Cancer Center
Una Hopkins, RN, FNP-BC, DNP – White Plains Hospital, Dickstein Cancer Treatment Center


Program Registration

This program has already taken place, to find information on upcoming programs, please check here.

SITC members are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current through 2018.

Click here to learn more about the registration rates for members and non-members for these programs.

ACI Post-Program Webinar

As a benefit of attending the ACI program, you have access to participate in two post-program webinars hosted by program organizers. The post-program webinars are another opportunity to ask questions, receive guidance from ACI program organizers, and to stay connected with program attendees. Mark your calendars for the post-program webinar dates:

Program Agenda

Preprogram Course: Introduction to Immunology

Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the program on March 24, 2018. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.

March 24, 2018  Program
5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.

Presentations include time for Audience Response System (ARS)-assisted audience interaction as well as general question and answer time.

7 – 8 a.m.

Check-in, Onsite Registration and Networking

Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice

Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy

8 – 8:05 a.m.

Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer

8:05 – 8:35 a.m.

Basic Principles of Cancer Immunotherapy
Kunle Odunsi, MD, PhD – Roswell Park Comprehensive Cancer Center

8:35 – 8:55 a.m.

Immunotherapy for the Treatment of Melanoma
­­­­­­­­­­­­­­­­
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center
­­­­­­­­­­­­­­­­

8:55 – 9:15 a.m.

Immunotherapy for the Treatment of Lung Cancer
Edwin Yau, MD, PhD – Roswell Park Comprehensive Cancer Center

9:15 – 9:35 a.m.

Immunotherapy for the Treatment of Genitourinary Cancers
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­
Saby George, MD, FACP – Roswell Park Comprehensive Cancer Center

9:35 – 9:55 a.m

Immunotherapy for the Treatment of Hematologic Malignancies
Philip L. McCarthy, MD – Roswell Park Comprehensive Cancer Center

9:55 – 10:15 a.m

Immunotherapy for the Treatment of Head and Neck Cancers
Dan P. Zandberg, MD – University of Maryland Greenebaum Comprehensive Cancer Center

10:15 – 10:25 a.m

 Break

Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice

10:25 – 10:30 a.m.

Information About the Society for Immunotherapy of Cancer Resources

10:30 – 11 a.m.

Effective Practices for Incorporating Immunotherapy Into Hospital Operations
Una Hopkins, RN, FNP-BC, DNP – White Plains Hospital, Dickstein Cancer Treatment Center

11 – 11:30 a.m.

Coverage and Reimbursement Challenges and Strategies
Una Hopkins, RN, FNP-BC, DNP – White Plains Hospital, Dickstein Cancer Treatment Center

11:30 – 11:35 a.m.

Take-Home Points for Part A

11:35 a.m. – noon

Lunch

Part B: Immune-Related Adverse Event (irAE) Management

noon – 12:20 p.m.

Mechanisms of Immune-Related Adverse Events
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center

12:20 – 12:50 p.m.

Management and Mitigation irAEs for Immunotherapy Prescribers
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center

12:50 – 1:20 p.m.

Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Alison Meagher, PharmD – Roswell Park Comprehensive Cancer Center

1:20 – 1:50 p.m.

Identification and Management of Immune-Related Adverse Events in the Emergency Setting
Amy Davis, MD – Magnolia Regional Health Center

1:50 – 1:55 p.m.

Posttest Questions by the Society for Immunotherapy of Cancer

1:55 – 2 p.m.

Take-Home Points for Part B and Closing Remarks


Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:

  • The rationale for common approaches to immunotherapy
  • The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
  • Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
  • The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through two post-program webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.

For more information, including program objectives, click here.

This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).      

                    

 

 


The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Incyte Corporation, Merck & Co., Inc. and Prometheus Laboratories Inc.


#ClinicalTrials #CNE #Clinician #Collaboration #SkinCancers #PresentationSlides #Vaccines #InPersonEvent #Toxicities #AlliedHealth #Industry #Immunomodulators #CombinationTherapy #LungCancers #HeadandNeckCancers #Pharmacist #Nurse #SITC #2017 #Oncologist #ImmuneCheckpointInhibitors #Adverse Events #AdvancesinCancerImmunotherapy(ACI) #HematologicMalignancies #CollaborativeEvent #Biomarkers #Introductory #CME #GenitourinaryCancers

Location

Embassy Suites by Hilton Buffalo
200 Delaware Avenue
Buffalo, NY 14202